OCP/DARS IDIQ 5 year purchase of cells

The Food and Drug Administration is forecasting a five-year indefinite-delivery, indefinite-quantity contract for the purchase of cells to support research in microphysiological systems, which are advanced in vitro models used to study human biology and disease responses. The procurement is classified under NAICS code 541714, indicating it pertains to biological research and development services, and is intended to secure a reliable supply of high-quality cellular materials essential for scientific evaluation and regulatory decision-making. This contract will enable ongoing research initiatives within the agency’s Center for Drug Evaluation and Research, focusing on predictive modeling and toxicological assessments that replicate human physiological conditions. The point of contact for program-related inquiries is the Cder Acquisition Liaison at cderacquisitions@fda.hhs.gov, while the contracting officer position is currently pending assignment. The opportunity is posted on the HHS OSDBU portal and does not specify a set-aside status, suggesting it is open to all eligible contractors without restrictions based on business size or ownership type. The place of performance and administrative details are not yet defined, indicating the procurement is in a pre-solicitation phase, with formal bidding anticipated following further planning and documentation. Stakeholders are encouraged to monitor the official portal for updates as the solicitation process advances toward a formal request for proposals.